Cargando…
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
CONTEXT: The role of somatostatin analogues (SSTa) in the treatment of acromegaly. OBJECTIVE: To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive to SSTa. DESIGN: An open, prospectiv...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974833/ https://www.ncbi.nlm.nih.gov/pubmed/17524029 http://dx.doi.org/10.1111/j.1365-2265.2007.02878.x |
_version_ | 1782135050234494976 |
---|---|
author | Maiza, Jean Christophe Vezzosi, Delphine Matta, Maria Donadille, Florence Loubes-Lacroix, Florence Cournot, Maxime Bennet, Antoine Caron, Philippe |
author_facet | Maiza, Jean Christophe Vezzosi, Delphine Matta, Maria Donadille, Florence Loubes-Lacroix, Florence Cournot, Maxime Bennet, Antoine Caron, Philippe |
author_sort | Maiza, Jean Christophe |
collection | PubMed |
description | CONTEXT: The role of somatostatin analogues (SSTa) in the treatment of acromegaly. OBJECTIVE: To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive to SSTa. DESIGN: An open, prospective, single-centre, clinical study. PATIENTS: Thirty-six acromegalic patients, aged 17–75 years (postoral glucose tolerance test GH > 1 µg/l, increased IGF-1 for age and sex), were monitored in a single centre and treated with SSTa as first-line therapy. The mean pretreatment GH level was 13·5 ±3·1 µg/l, and IGF-1 (as a percentage of the value over the normal range) was 302 ± 26%. The patients had macroadenoma (n = 25), microadenoma (n = 8) or empty sella turcica (n = 3). The mean duration of treatment was 8 years (range 3–18 years). Hormonal and morphological monitoring was undertaken after 6 months, and then the patients were followed annually. RESULTS: After 1 year, the mean GH and IGF-1 levels had reduced considerably (GH: 2·4 ± 0·3 µg/l; IGF-1; 174 ± 14%, P < 0·01), and they continued to decrease over 10 years, with a mean GH level of 1·6 ± 0·1 µg/l and IGF-1 of 123 ± 18% (P = 0·02). GH < 2 µg/l, normal IGF-1, or both were observed in 25 (70%), 24 (67%) and 21 (58%) patients, respectively. The mean reduction in tumour volume was 43% (range 13–97%) and shrinkage > 20% was obtained in 21 patients (72%). SSTa treatment was well tolerated with few digestive or metabolic side-effects. CONCLUSION: Long-term (up to 18 years) treatment with SSTa used as first-line therapy is effective from both an antihormonal and antitumour perspective, and is well tolerated in acromegalic patients. |
format | Text |
id | pubmed-1974833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-19748332007-09-10 Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa Maiza, Jean Christophe Vezzosi, Delphine Matta, Maria Donadille, Florence Loubes-Lacroix, Florence Cournot, Maxime Bennet, Antoine Caron, Philippe Clin Endocrinol (Oxf) Original Articles CONTEXT: The role of somatostatin analogues (SSTa) in the treatment of acromegaly. OBJECTIVE: To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive to SSTa. DESIGN: An open, prospective, single-centre, clinical study. PATIENTS: Thirty-six acromegalic patients, aged 17–75 years (postoral glucose tolerance test GH > 1 µg/l, increased IGF-1 for age and sex), were monitored in a single centre and treated with SSTa as first-line therapy. The mean pretreatment GH level was 13·5 ±3·1 µg/l, and IGF-1 (as a percentage of the value over the normal range) was 302 ± 26%. The patients had macroadenoma (n = 25), microadenoma (n = 8) or empty sella turcica (n = 3). The mean duration of treatment was 8 years (range 3–18 years). Hormonal and morphological monitoring was undertaken after 6 months, and then the patients were followed annually. RESULTS: After 1 year, the mean GH and IGF-1 levels had reduced considerably (GH: 2·4 ± 0·3 µg/l; IGF-1; 174 ± 14%, P < 0·01), and they continued to decrease over 10 years, with a mean GH level of 1·6 ± 0·1 µg/l and IGF-1 of 123 ± 18% (P = 0·02). GH < 2 µg/l, normal IGF-1, or both were observed in 25 (70%), 24 (67%) and 21 (58%) patients, respectively. The mean reduction in tumour volume was 43% (range 13–97%) and shrinkage > 20% was obtained in 21 patients (72%). SSTa treatment was well tolerated with few digestive or metabolic side-effects. CONCLUSION: Long-term (up to 18 years) treatment with SSTa used as first-line therapy is effective from both an antihormonal and antitumour perspective, and is well tolerated in acromegalic patients. Blackwell Publishing Ltd 2007-08-01 /pmc/articles/PMC1974833/ /pubmed/17524029 http://dx.doi.org/10.1111/j.1365-2265.2007.02878.x Text en © 2007 The Authors Journal compilation © 2007 Blackwell Publishing Ltd https://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2·5, which does not permit commercial exploitation. |
spellingShingle | Original Articles Maiza, Jean Christophe Vezzosi, Delphine Matta, Maria Donadille, Florence Loubes-Lacroix, Florence Cournot, Maxime Bennet, Antoine Caron, Philippe Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa |
title | Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa |
title_full | Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa |
title_fullStr | Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa |
title_full_unstemmed | Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa |
title_short | Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa |
title_sort | long-term (up to 18 years) effects on gh/igf-1 hypersecretion and tumour size of primary somatostatin analogue (ssta) therapy in patients with gh-secreting pituitary adenoma responsive to ssta |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974833/ https://www.ncbi.nlm.nih.gov/pubmed/17524029 http://dx.doi.org/10.1111/j.1365-2265.2007.02878.x |
work_keys_str_mv | AT maizajeanchristophe longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT vezzosidelphine longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT mattamaria longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT donadilleflorence longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT loubeslacroixflorence longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT cournotmaxime longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT bennetantoine longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta AT caronphilippe longtermupto18yearseffectsonghigf1hypersecretionandtumoursizeofprimarysomatostatinanaloguesstatherapyinpatientswithghsecretingpituitaryadenomaresponsivetossta |